Zydus Lifesciences Strikes Gold: Cancer-Risk Testing Pact with Myriad Genetics!

Partnership Unveiled

The deal positions Zydus as the exclusive partner for Myriad's hereditary cancer screening portfolio, targeting BRCA1/2 mutations and 35+ genes linked to breast, ovarian, and other cancers. It aligns with India's National Cancer Control Programme, addressing 1.4 million new cases annually.

Key Highlights

Test Portfolio: myRisk® panels for comprehensive risk assessment; BRACAnalysis CDx for targeted therapies like PARP inhibitors.

Market Impact: First-mover advantage in precision oncology; aims to screen 1 million high-risk women in 3 years.

Strategic Fit: Bolsters Zydus' diagnostics arm post-COVID testing surge; Myriad gains foothold in $50 bn Indian healthcare market.

Commercial Rollout: Launches Q1 2026 across 200+ labs; pricing at ₹15,000-25,000 per test for accessibility.

Health Revolution Ahead

This tie-up accelerates genomic adoption, potentially slashing cancer mortality by 30% through proactive screening.

Sources: BSE Announcements, Zydus Lifesciences Press Release, Economic Times Pharma Coverage.​